Stifel Financial
NAMS icon

Stifel Financial’s NewAmsterdam Pharma NAMS Stock Holding History

Stifel Financial’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08M Buy
31,851
+2,630
+9% +$86.7K ﹤0.01% 2503
2026
Q1 		$935K Buy
+29,221
New +$952K ﹤0.01% 2488

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Stifel Financial's NAMS Position: Q2 2026 in Review

Stifel Financial increased its NewAmsterdam Pharma (NAMS) stake by 9% in Q2 2026, buying an estimated $86.7K and bringing the position to 31,851 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #2503.

Stifel Financial first reported a position in NAMS in Q1 2026 and has held it in 2 quarters since. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Stifel Financial held 31,851 shares of NewAmsterdam Pharma worth $1.08M as of Q2 2026.
  • Stifel Financial bought 2,630 NewAmsterdam Pharma shares in Q2 2026, an estimated $86.7K.
  • NewAmsterdam Pharma made up ﹤0.01% of Stifel Financial's portfolio in Q2 2026, its #2503 holding.
  • Stifel Financial first reported a position in NewAmsterdam Pharma in Q1 2026 and has held it in 2 quarters since.
  • 194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Stifel Financial's 13F filing for Q2 2026, filed 12 Aug 2026.